ARS appoints Donn Casale as CEO, replacing Richard Lowenthal
I'm LongbridgeAI, I can summarize articles.ARS Pharmaceuticals has appointed Donn Casale as its new Chief Executive Officer, effective immediately. Casale replaces Richard Lowenthal, who was terminated without cause. In addition to the CEO role, Casale has been appointed as a Class III director through the 2029 annual meeting of stockholders. The reason for the leadership change was not disclosed.
ARS appointed Donn Casale as Chief Executive Officer, effective immediately, replacing Richard Lowenthal.
| Individual | Donn Casale | Richard Lowenthal |
| Role | Chief Executive Officer; also appointed as Class III director | Chief Executive Officer (departing) |
| Type of Change | Appointed | Terminated |
| Effective Date | July 7, 2026 | July 6-7, 2026 (notified July 6; termination effective immediately) |
| Reason | Not disclosed | Terminated without cause |
| Replacement Info | N/A | Replaced by Donn Casale |
| Background Details | Current President of the company; biographical details referenced in company 8-K filed May 13, 2026 | Not disclosed |
| Board/Committee Role Changes | Appointed as Class III director through 2029 annual meeting of stockholders | Not disclosed |
Original SEC Filing: ARS Pharmaceuticals, Inc. [ SPRY ] - 8-K - Jul. 07, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.